BMS-986488 + adagrasib + cetuximab

BMS-986488 + adagrasib + cetuximab is a three-drug experimental combination currently investigated for the treatment of advanced solid tumors, especially colorectal cancer (CRC) with KRAS G12C mutations. **BMS-986488** is an investigational immunotherapy from Bristol Myers Squibb with an undisclosed modality, being tested primarily in solid tumor oncology settings. **Adagrasib** (brand name: Krazati) is a small molecule inhibitor specifically targeting KRAS G12C, directly inhibiting this oncogenic driver. **Cetuximab** (brand name: Erbitux) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is used for its antitumor effects in various epithelial cancers. The combination aims to provide synergistic inhibition of KRAS-driven signaling and EGFR in KRAS G12C-mutated cancers.